SHSue Han

Sue Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sue Han has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nanoscopy reveals heparan sulfate clusters as docking sites for SARS-CoV-2 attachment and entry

    by Sue Han, Xin Wang, Tiansheng Li, Ammar Mohseni, Ivan Kosik, Chung Yu Chan, Alberto Domingo López-Muñoz, Jessica Matthias, Reid Suddaby, Zhixiong Wang, et al.

    Virus entry is thought to involve binding a unique receptor for cell attachment and cytosolic entry. For SARS-CoV-2 underlying the COVID-19 pandemic, angiotensin-converting enzyme 2 (ACE2) is widely considered the receptor for cell-surface attachment and subsequent cell entry. Using advanced light microscopy to resolve individual virions and receptors, we found instead that heparan sulfate (HS), not ACE2, mediates SARS-CoV-2 cell-surface attachment, and subsequent endocytosis. ACE2 functions only downstream of HS to enable viral genome expression. Instead of binding single HS molecules that electrostatically interact with viral surface proteins weakly, SARS-CoV-2 binds clusters of ~6–137 HS molecules projecting 60–410 nm above the plasma membrane. These tall, HS-rich clusters, present at about one per 6 μm², act as docking sites for viral attachment. Blocking HS binding with the clinically used HS-binding agent pixantrone strongly inhibited an authentic pathogen, the SARS-CoV-2 Omicron JN.1 subvariant, from attaching to and infecting human airway cells. This work establishes a revised entry paradigm in which HS clusters mediate SARS-CoV-2 attachment and endocytosis, with ACE2 acting downstream, thereby identifying HS interactions as a key anti-COVID-19 strategy. This paradigm and its therapeutic implications may apply broadly beyond COVID-19 because, analogous to SARS-CoV-2, HS binds many other viruses but is only considered an attachment regulator.

  • Open Access

    Nanoscopy Reveals Heparan Sulfate Clusters as Docking Sites for SARS-CoV-2 Attachment and Entry

    by Sue Han, Xin Wang, Tiansheng Li, Ammar Mohseni, Ivan Kosik, Chung Yu Chan, Alberto Domingo López-Muñoz, Jessica Matthias, Reid Suddaby, Zhixiong Wang, et al.

    Virus entry is thought to involve binding a unique receptor for cell attachment and cytosolic entry. For SARS-CoV-2 underlying the COVID-19 pandemic, angiotensin-converting enzyme 2 (ACE2) is widely considered the receptor for cell-surface attachment and cytosolic entry. Using advanced light microscopy to resolve individual virions and receptors, we found instead that heparan sulfate (HS), not ACE2, mediates SARS-CoV-2 cell-surface attachment and subsequent endocytosis. ACE2 functions only downstream of HS to enable viral genome expression. Instead of binding single HS molecules that electrostatically interact with viral surface proteins weakly, SARS-CoV-2 binds clusters of ∼6–137 HS molecules projecting 60–410 nm above the plasma membrane. These tall, HS-rich clusters, present at about one per 6 μm², act as docking sites for viral attachment. Blocking HS binding with the clinically used HS-binding agent pixantrone strongly inhibited an authentic pathogen, the SARS-CoV-2 Omicron JN.1 subvariant, from attaching to and infecting human airway cells. This work establishes a revised entry paradigm in which HS clusters mediate SARS-CoV-2 attachment and endocytosis, with ACE2 acting downstream, thereby identifying HS interactions as a key anti-COVID-19 strategy. This paradigm and its therapeutic implications may apply broadly beyond COVID-19 because, analogous to SARS-CoV-2, HS binds many other viruses but is only considered an attachment regulator.

  • Open Access

    Editorial: Methods in cellular neurobiology research

    by Sue Han, Adalberto Merighi, Cheng Wang, Shrijeet Chakraborti

    Vesicle analysis, further demonstrate how methodological innovation is reshaping our understanding of non-neuronal contributions to disease. This Research Topic, Methods in Cellular Neuroscience, brings together contributions that exemplify the breadth and creativity of current methodological approaches. Collectively, these studies illustrate how technical innovation not only expands our experimental repertoire but also drives conceptual advances across the spectrum of cellular neuroscience, from basic mechanisms of excitability to translational models of neurological disease. Why now? In neuroscience, there are three bottlenecks that hinder progress: 1) visualization of the right cell and structures with sufficient spatiotemporal resolution; 2) testing mechanisms in complementary model systems; and 3) turning mechanistic insights into better biomarkers, targets, or interventions of neurological disorders. The five articles in this Topic contribute to each bottleneck from a different angle.The Research Topic begins with a comprehensive review, "An electrophysiologist's guide to dorsal horn excitability and pain". I. Arconada et al. synthesize intrinsic and synaptic determinants of dorsal horn firing (Na + , K + , HCN, GIRK, Ca 2+ -activated K + currents), emphasizing strong cellular heterogeneity and the limits of predicting biochemical phenotype or morphology from firing patterns. This framework guides interpretation of circuit plasticity in injury and inflammation. In another method paper, C. Humpel introduces a microcontact-printing method that deposits antibodies for GFAP and laminin directly onto 150 µm organotypic slices, enabling week-scale live imaging on standard inverted microscopes. The approach supports patterned, local delivery, lowers costs, and reduces animal use, expanding access to vascular-glial studies. In a research article, A. Otomo et al. use a compartmentalized microfluidic chip to examine early axonal phenotypes in iPSCderived motor neurons carrying FUS/TLS mutations. By DIV7 they detect growth restriction and altered mitochondrial trafficking; viability remains comparable early but declines by days 14 and 21, and stress worsens deficits. The platform yields tractable readouts for mechanism and drug discovery. In another interesting research article, X. Zhang et al. report that memantine-preconditioned MSC-derived extracellular vesicles (EVs), enriched in miR-139-5p and miR-133b, outperform conventional EVs in a mouse photothrombotic stroke model. These EVs improve functional recovery, reduce infarct burden, mitigate excitotoxicity, and activate neuroregenerative pathways, illustrating microenvironment-tailored EV engineering. Finally, A. K. Torres et al. review C. elegans as a fast, genetically precise system to interrogate proteinopathy, aging, and neuron-glia interactions. Tools such as transgenics, inducible expression, and pharmacology create efficient pipelines that bridge in vitro assays and mammalian studies. Together, these contributions span ionic mechanisms, accessible imaging platforms, disease modeling, and translational strategies, offering practical methods and conceptual clarity for probing and modulating neural systems in health and disease.Taken together, this collection shows how method innovation is already widening the three bottlenecks we outlined. Patterned microcontact printing is breaking the resolution barrier, making it possible to conduct weeks-long, low-cost live imaging of astroglia-vessel dynamics in organotypic slices. This gives standard microscopes routine access to glial biology and neurovascular remodeling. Utilizing a compartmentalized microfluidic platform, researchers can now perform precise mechanism testing by deriving quantitative axonal-phenotype assays from patient iPSC motor neurons. This technique is powerful because it captures axonal growth and mitochondrial trafficking defects before degeneration, accelerating ALS research and drug screening. For translational impact, a targeted approach involves preconditioning mesenchymal-stromal-cell extracellular vesicles with an NMDAR inhibitor. This strategic modification reprograms the EV cargo for better efficacy, successfully helping to mitigate excitotoxicity and promote neurorepair in stroke models. It directly links mechanistic insight to therapeutic intervention. Model diversity is strengthened by a concise electrophysiological framework for dorsal horn excitability that anchors cellular heterogeneity to pain phenotypes, and by C. elegans pipelines that rapidly connect proteinopathy and neuron-glia interactions to conserved targets, streamlining paths from discovery to mammalian validation. Together, these methods equip cellular neuroscience to interrogate fundamental circuit rules, glia-vascular crosstalk, and neurodegenerative pathways, while building tractable routes from basic science to interventions across pain, stroke, and other neurological diseases. Overall, the work presented provides a strong foundation for future studies aiming to unravel the complexities of the nervous system in health and disease.

  • Open Access

    A phosphoinositide switch from PI(4,5)P 2 to PI4P triggers endocytosis by inducing dynamin-mediated fission in secretory cells

    by Xiaoli Guo, Lisi Wei, Nidhi Kundu, Wonchul Shin, Chung Yu Chan, Sue Han, Ammar Mohseni, Maryam Molakarimi, Min Sun, Xin-Sheng Wu, et al.

    Endocytosis generates life-essential vesicles via complex protein-lipid machinery, yet its initiation mechanisms remain elusive. Long thought to require full machinery spatiotemporal coordination to drive the flat-to-round vesicle transformations, we reveal a notably simple initiation mechanism in neuroendocrine chromaffin cells involving only the final step, the pore closure. During calcium-triggered exocytosis, calcium activates the phosphatase synaptojanin, rapidly converting PI(4,5)P 2 to PI4P. Elevated PI4P drives the fission enzyme dynamin to close the pores of preexisting and exocytosis-generated Ω-profiles, which are sufficient to generate slow, fast, ultrafast, overshoot, and bulk endocytosis, and kiss-and-run (fusion pore closure). These findings resolve the long-standing mystery of endocytosis and fission initiation and reveal PI4P, not the widely assumed PI(4,5)P 2 , as the key lipid for dynamin-mediated fission. This pathway is clinically important, as it is impaired by synaptojanin mutations associated with Parkinson’s disease and seizures, and is likely disrupted in other disorders involving PI4P or PI(4,5)P 2 dysregulation.


  • Open Access

    Nanoscopy Reveals Heparan Sulfate Clusters as Docking Sites for SARS-CoV-2 Attachment and Entry

    by Sue Han, Xin Wang, Tiansheng Li, Ammar Mohseni, Ivan Kosik, Chung Yu Chan, Alberto Domingo López-Muñoz, Jessica Matthias, Reid Suddaby, Zhixiong Wang, et al.

    Virus entry is thought to involve binding a unique receptor for cell attachment and cytosolic entry. For SARS-CoV-2 underlying the COVID-19 pandemic, angiotensin-converting enzyme 2 (ACE2) is widely considered the receptor for cell-surface attachment and cytosolic entry. Using advanced light microscopy to resolve individual virions and receptors, we found instead that heparan sulfate (HS), not ACE2, mediates SARS-CoV-2 cell-surface attachment and subsequent endocytosis. ACE2 functions only downstream of HS to enable viral genome expression. Instead of binding single HS molecules that electrostatically interact with viral surface proteins weakly, SARS-CoV-2 binds clusters of ∼6–137 HS molecules projecting 60–410 nm above the plasma membrane. These tall, HS-rich clusters, present at about one per 6 μm², act as docking sites for viral attachment. Blocking HS binding with the clinically used HS-binding agent pixantrone strongly inhibited an authentic pathogen, the SARS-CoV-2 Omicron JN.1 subvariant, from attaching to and infecting human airway cells. This work establishes a revised entry paradigm in which HS clusters mediate SARS-CoV-2 attachment and endocytosis, with ACE2 acting downstream, thereby identifying HS interactions as a key anti-COVID-19 strategy. This paradigm and its therapeutic implications may apply broadly beyond COVID-19 because, analogous to SARS-CoV-2, HS binds many other viruses but is only considered an attachment regulator. Statement of Significance: Viral entry, a crucial antiviral target, is typically thought to involve binding its unique receptor for the cell surface attachment and subsequent entry. We examined this concept with advanced microscopies to resolve individual receptors and SARS-CoV-2 virions responsible for the COVID-19 pandemic. We discovered two receptors for viral entry: heparan sulfate, a polysaccharide that may bind many viruses, mediates viral attachment and subsequent endocytosis, whereas angiotensin-converting enzyme 2 (ACE2), the generally assumed SARS-CoV-2 receptor, acts only downstream to facilitate viral infection. This model suggests perturbation of HS binding as a more effective anti-COVID-19 strategy than previously recognized. It may apply broadly beyond COVID-19 because, analogous to SARS-CoV-2, HS binds many other viruses but is only considered an attachment regulator.

  • Open Access

    Real-time visualization of exo- and endocytosis membrane dynamics with confocal and super-resolution microscopy

    by Xiaoli Guo, Sue Han, Lisi Wei, Gianvito Arpino, Wonchul Shin, Xin Wang, Ling-Gang Wu


  • Confocal Microscopy to Measure Three Modes of Fusion Pore Dynamics in Adrenal Chromaffin Cells

    by Sue Han, Xin Wang, Nicholas Cordero, Ling-Gang Wu

    Dynamic fusion pore opening and closure mediate exocytosis and endocytosis and determine their kinetics. Here, it is demonstrated in detail how confocal microscopy was used in combination with patch-clamp recording to detect three fusion modes in primary culture bovine adrenal chromaffin cells. The three fusion modes include 1) close-fusion (also called kiss-and-run), involving fusion pore opening and closure, 2) stay-fusion, involving fusion pore opening and maintaining the opened pore, and 3) shrink-fusion, involving shrinkage of the fusion-generated Ω-shape profile until it merges completely at the plasma membrane. To detect these fusion modes, the plasma membrane was labeled by overexpressing mNeonGreen attached with the PH domain of phospholipase C δ (PH-mNG), which binds to phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) at the cytosol-facing leaflet of the plasma membrane; vesicles were loaded with the fluorescent false neurotransmitter FFN511 to detect vesicular content release; and Atto 655 was included in the bath solution to detect fusion pore closure. These three fluorescent probes were imaged simultaneously at ~20-90 ms per frame in live chromaffin cells to detect fusion pore opening, content release, fusion pore closure, and fusing vesicle size changes. The analysis method is described to distinguish three fusion modes from these fluorescence measurements. The method described here can, in principle, apply to many secretory cells beyond chromaffin cells.


  • Open Access

    Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma

    by Victor Ruiz-Rodado, Tomohiro Seki, Tyrone Dowdy, Adrian Lita, Meili Zhang, Sue Han, Chunzhang Yang, Murali K. Cherukuri, Mark R. Gilbert, Mioara Larion

    Understanding the metabolic reprogramming of aggressive brain tumors has potential applications for therapeutics as well as imaging biomarkers. However, little is known about the nutrient requirements of isocitrate dehydrogenase 1 (IDH1) mutant gliomas. The IDH1 mutation involves the acquisition of a neomorphic enzymatic activity which generates D-2-hydroxyglutarate from α-ketoglutarate. In order to gain insight into the metabolism of these malignant brain tumors, we conducted metabolic profiling of the orthotopic tumor and the contralateral regions for the mouse model of IDH1 mutant glioma; as well as to examine the utilization of glucose and glutamine in supplying major metabolic pathways such as glycolysis and tricarboxylic acid (TCA). We also revealed that the main substrate of 2-hydroxyglutarate is glutamine in this model, and how this re-routing impairs its utilization in the TCA. Our 13C tracing analysis, along with hyperpolarized magnetic resonance experiments, revealed an active glycolytic pathway similar in both regions (tumor and contralateral) of the brain. Therefore, we describe the reprogramming of the central carbon metabolism associated with the IDH1 mutation in a genetically engineered mouse model which reflects the tumor biology encountered in glioma patients.


  • Open Access

    mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma

    by Yang Liu, Yanxin Lu, Aiguo Li, Orieta Celiku, Sue Han, Mingyu Qian, Chunzhang Yang

    Isocitrate dehydrogenase (IDH) mutations are common genetic abnormalities in lower grade gliomas. The neomorphic enzyme activity of IDH mutants leads to tumor formation through epigenetic alteration, dysfunction of dioxygenases, and metabolic reprogramming. However, it remains elusive as to how IDH mutants regulate the pathways associated with oncogenic transformation and aggressiveness. In the present study, by using unbiased transcriptomic profiling, we showed that IDH1 mutations result in substantial changes in the gene sets that govern cellular motility, chemotaxis, and invasion. Mechanistically, rapamycin-insensitive companion of mammalian target of rapamycin (Rictor)/Ras-related C3 botulinum toxin substrate 1 (Rac1) signaling plays an essential role in the motility and proliferation of IDH1-mutated cells by prompting cytoskeleton reorganization, lamellipodia formation, and enhanced endocytosis. Targeting the Rictor/Rac1 pathway suppresses IDH1-mutated cells by limiting endocytosis and cell proliferation. Overall, our findings indicate a novel metabolic reprogramming mechanism of IDH1-mutated cells by exploiting metabolites from the extracellular milieu. Targeting the Rictor/Rac1 pathway could be an alternative therapeutic strategy for IDH1-mutated malignancies.